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activation in primary and chronic HIV
infection
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Abstract
Background: Kynurenine/Tryptophan ratio (KTR) is increased in HIV infection, and linked to immune activation. We
hypothesized that early cART initiation results in lower KTR compared to late initiation. Furthermore, we
hypothesized that KTR prior to cART is a predictor of the magnitude of subsequent reduction in immune activation.
Methods: Prospective study including 57 HIV-infected individuals (primary HIV infection (N = 14), early presenters
(>350 CD4+ T cells/μL, N = 24), late presenters (<200 CD4+ T cells/μL, N = 19)). Kynurenine and tryptophan were
analysed by liquid chromatography–tandem mass spectrometry. Total CD4+ and CD8+ T cells were determined
and proportion of activated CD38 + HLA-DR+ Tcells was measured using flow cytometry at baseline and after 6
and 12 months of cART.
Results: At baseline, primary HIV infection had higher KTR than early presenters. However, similar KTR in primary
HIV infection and early presenters was found after cART initiation, while late presenters had higher KTR at all time
points. In primary HIV infection and early presenters, KTR was positively associated with proportion of activated cells
at baseline. Furthermore, in early presenters the KTR at baseline was associated with proportion of activated cells
after 6 and 12 months. Interestingly, in primary HIV infection the KTR at baseline was positively associated with
reduction in proportion of CD8 + CD38 + HLA-DR T cells after 6 and 12 months.
Conclusions: Lower kynurenine/tryptophan ratio during follow-up was found after early initiation of cART. KTR in
primary HIV infection and early presenters was positively associated with immune activation. Importantly, KTR in
primary HIV infection predicted the magnitude of subsequent reduction in immune activation. Thus, a beneficial
effect of early cART on KTR was suggested.
Keywords: HIV, Kynurenine/Tryptophan ratio, Primary HIV infection, Immune activation
Background
Primary HIV infection is characterized by rapid deple-
tion of CD4+ T-cells, high viral load, and the establish-
ment of a chronic state of immune activation [1]. The
magnitude of these three events has been shown to be
closely related to the long term prognosis in HIV-
infected individuals [2, 3]. Thus, higher CD4+ T-cell
counts and lower levels of chronic immune activation
are associated with a better clinical outcome [4, 5].
Tryptophan is an essential amino-acid, metabolized by
the kynurenine pathway. Rate-limiting factors in this
pathway are Tryptophan 2,3-dioxygenase (TDO) and
Indoleamine 2,3-dioxygenase (IDO). TDO and IDO are
active mainly in physiological conditions and conditions
characterized by immune activation, respectively [6, 7].
Furthermore, minor amounts of IDO-like enzymes are
produced by gut bacteria [8]. This activity has been de-
scribed to be enhanced in HIV-infected individuals [8,
9].IDO catalyzes the catabolism of tryptophan to N-
formylkynyrenine, which is rapidly decomposed to
kynurenine [10, 11]. Thus, the ratio between kynurenine
and tryptophan (KTR) in plasma can be used as an in-
direct measure of IDO activity [12]. Increased KTR has
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been described in numerous conditions characterized by
low grade inflammation, such as Alzheimer’s disease,
cancer, and viral infections [13, 14]. We and other
groups have described an increased KTR in HIV infec-
tion [6, 9, 15–19]. Tryptophan catabolites, in particular
kynurenine and quinolinic acid, are associated with im-
mune activation [20, 21], and increased KTR is associ-
ated with a higher level of immune activation in
untreated HIV-infected individuals [15, 22]. Further-
more, tryptophan catabolism has been linked to CD4+
immune regulation. In particular, an inverse association
between KTR and the ratio between Th17 cells and T
regulatory cells in both primary and chronic phases of
HIV infection has been described [12, 23].
An early initiation of combination antiretroviral ther-
apy (cART) is associated with both a lower level of im-
mune activation and faster CD4+ T-cell recovery
compared to initiation of treatment in later stages of
HIV infection [24, 25]. A reduction of KTR following
cART initiation has been described by several recent
studies [6, 15, 17–19]. However, it is unclear whether
early initiation of cART results in a greater reduction or
even normalization of the KTR set point compared to
cART initiation in late presenting HIV infection.
In the present study, we hypothesized that early initi-
ation of cART during primary HIV infection or in early
presenting patients with CD4+ T cell counts above 350
cells/μL results in improved KTR set point compared to
initiation of cART in late presenters with CD4 T cell
counts below 200 cells/μL. Furthermore, we hypothe-
sized that KTR before initiation of cART is a predictor
of both CD4 T-cell recovery and the magnitude of the
subsequent reduction in immune activation. To investi-
gate this, KTR was measured before initiation of cART
and after 6 and 12 months of cART in individuals with
either primary HIV infection or chronic HIV infection.
To our knowledge, this is the first prospective study of
KTR in a cohort including both individuals with primary
and chronic HIV infection.
Methods
Study population
A total of 100 HIV-infected individuals that initiated
cART were included in a prospective cohort study [26],
and plasma samples were obtained at baseline, and at 6,
12, and 24 months after initiation of cART as previously
described [26]. Inclusion criteria were a positive HIV-1
test and initiation of cART. Decision about cART initi-
ation was made by the patient’s physician and the pa-
tient, and participation in this study did not influence
this decision. All individuals were enrolled from Depart-
ment of Infectious Diseases, Rigshospitalet, Copenhagen
University Hospital or Department of Infectious Dis-
eases, Hvidovre Hospital. In the present study, 57
treatment naïve HIV-infected individuals were included.
We included all patients from the cohort belonging to
either of the three groups: primary HIV infection
(N = 14), early presenters (>350 CD4+ T cells/μL at
baseline, N = 24), or late presenters (<200 CD4+ T cells/
μL at baseline, N = 19) and with plasma samples avail-
able both at baseline and at least at one of time points 6
and 12 months of follow-up. Only few samples were
available at 24 months of follow-up, these samples were
therefore not included in the present study. A total of 14
individuals were defined as having primary HIV infec-
tion, i.e. they had a negative HIV test less than 6 months
prior to diagnosis and/or one or more negative bands in
Western Blot. Fiebig stages for individuals with primary
HIV infection were as follows: I, N = 1; II, N = 1; III,
N = 1; IV, N = 11. Furthermore, 16 healthy individuals
were included as healthy controls. No differences in age
and sex distributions were found between the groups
(Table 1).
Written informed consent was obtained from all par-
ticipants, and the study was performed in accordance
with the ethical guidelines of the 1975 Declaration of
Helsinki and approved by the Local Ethical Committee
(H-3-2011-089) and the Danish Data Protection Agency.
Collection of blood samples and flow cytometry
Blood samples from HIV-infected individuals were col-
lected at the day of inclusion (baseline/day 0 of cART)
and after 6 and 12 months of cART. Blood samples from
healthy controls were only collected once at the time of
inclusion. The numbers of samples available at each
timepoint (baseline, 6, and 12 months after initiation of
cART) were: primary HIV infection: 14, 11, 7; early pre-
senters: 24, 22, 8; late presenters: 19, 10, 8.
Blood collected in ethylenediamine tetraacetic acid
(EDTA) tubes was used for flow cytometry as described
previously [26]. In brief, 100 μL of EDTA blood was in-
cubated with fluorescent dye–conjugated monoclonal
antibodies, erythrocytes were lysed with 2 mL of Lysing
Solution (Becton Dickinson (BD), Franklin Lakes, NJ,
USA), and the samples were washed and resuspended in
Facs flow (BD). CD3 in combination with CD8 or CD4
was used to characterize T cells, and chronic activated
CD4+ and CD8+ T cells were determined as proportion
of CD4 + CD38 + HLA-DR+ and CD8 + CD38 + HLA-
DR+ T cells, respectively. Acquisition was performed
using a FACS Canto, and data were processed using
FACS Diva software (BD). Monoclonal antibodies used
to determine lymphocyte subsets were CD3 FITC, CD4
APC-Cy7-A, CD8- PerCP-Cy5–5-A, CD38 PE-Cy7-A,
and HLA-DR APC-A and appropriate isotype controls
all purchased from BD. For each sample a minimum of
100,000 cells were acquired and gated as previously de-
scribed by our group [27] Lymphocyte subsets are given
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as the proportion (%) of the cell population concerned
(CD4+ T cells or CD8+ T cells).
Furthermore, the reduction of immune activation after
initiation of cART was determined as the difference be-
tween proportion of CD4+ or CD8+ T cells expressing
CD38 + HLA-DR+ at baseline and after 6 and 12 months
of follow-up (Δ % CD8 + CD38 + HLA-DR+ T cells = %
CD8 + CD38 + HLA-DR+ T cells at one of the follow-
up time points – % CD8 + CD38 + HLA-DR+ T cells at
baseline).
Kynurenine and tryptophan
Kynurenine and tryptophan were analysed at BEVITAL
(www.bevital.no) by liquid chromatography–tandem
mass spectrometry (LC-MS/MS) as previously described
[28], and kynurenine/tryptophan ratio (KTR) was used
as a measure of IDO-1 activation [12]. In the interest of
clarity, the ratio is multiplied by 1000 and expressed as
the KTR in this study.
Statistical analysis
Parametric or non-parametric tests were used as appro-
priate. Differences between the groups of HIV-infected
individuals were evaluated by one way ANOVA test
(Kruksal-Wallis test in case of non-parametric distribu-
tion) and if significant followed by unpaired t tests or by
Mann-Witney U tests in case of non-parametric distribu-
tion. The effect of baseline measures of KTR on immune
recovery and immune activation after initiating cART were
evaluated by Pearson’s and Spearman’s test, as appropriate.
Two-tailed P-values <0.05 were considered significant. All
statistical analyses were performed using SPSS (version 22
- IBM corp., Armonk, New York, USA).
Results
CD4+ and CD8+ T cell count and immune recovery
Clinical characteristics of the study populations are pre-
sented in Table 1.
At baseline, individuals with primary HIV infection
and early presenters had comparable CD4+ T cell
counts, while late presenters had lower CD4+ T cell
counts than the two other groups (Table 1). Further-
more, at baseline all groups of HIV-infected individuals
had lower CD4+ T cell counts than healthy controls
(Table 1). No differences in CD8+ T cell count were
found between groups. No differences in CD4+ T cell re-
covery (increase in CD4+ T cell count from baseline to a
time of follow-up) were found between any of the
groups of HIV-infected individuals at any time point. Re-
sults regarding immune recovery for the entire cohort
have been presented in previous studies [26, 29].
KTR in plasma
At baseline, KTR in individuals with primary HIV infec-
tion was higher than in early presenters and lower than in
late presenters (Table 1). However, similar KTR in individ-
uals with primary HIV infection and early presenters was
found after 6 and 12 months of cART. In contrast, late
presenters maintained higher KTR at 6 and 12 months of
cART compared to both primary HIV infection and early
presenters (Fig. 1a). Furthermore, all groups of HIV-
infected individuals (primary HIV infection, early
Table 1 Clinical characteristics of the study population
Primary HIV infection
N = 14
Early presenters
N = 24
Late presenters
N = 19
Healthy controls
N = 16
P
Gender, males/females, (% males) 13/1 (92.9) 22/2 (91.7) 18/1 (94.7) 15/1 (93.8) .948
Age, years, mean (SD) 46 (8.9) 45 (8.2) 47 (10.1) 43 (9.4) .529
CD8+ at baseline, cells/μL, mean (SD) 1238.6 (659.8) 1123.5 (547.5) 820.1 (556.0) 915.7 (409.7) .116
CD4+ at baseline, cells/μL, mean (SD) 577.8 (228.5) a,d 527.9 (111.2)c,f 72.7 (62.7)a,c,e 1144.0 (329.0)d,e,f < .001
CD4/CD8 at baseline, mean (SD) 0.6 (0.4)a,d 0.6 (0.2)c,f 0.1 (0.1)a,c,e 1.4 (0.5)d,e,f < .001
Co-infection with chronic HBV/HCV, N 0/1 1/0 0/2 0/0 NA
HIV RNA at baseline, mean (SD) 2,413,322 (4,119,479)a,b 97,328 (253,967)b,c 486,483 (524,072)a,c NA < .001
AIDS defining events, N 0 0 1 NA NA
KTratio at baseline, mean (SD) 46.8 (20.3)a,b,d 34.8 (10.6)b,c,f 74.5 (48.1)a,c,e 20.9 (3.7)d,e,f < .001
CD8 + CD38 + HLA-DR+, % cells, mean (SD) 44.7 (20.3) a,b,d 22.0 (13.4)b,c,f 25.5 (21.3)a,c,e 1.3 (0.8)d,e,f < .001
CD4 + CD38 + HLA-DR+, % cells, mean (SD) 5.5 (4.1)a,d 3.5 (3.0)c,f 15.5 (15.4)a,c,e 0.8 (0.6)d,e,f < .001
P*: comparing the four groups by using ANOVA if parametric variables or Kruksal-Wallis test if non parametric variables. If significant (<0.05) then t-test if parametric
variables or Mann-Whitney if non parametric variables were used to compare two groups. Only significant differences are marked:
aprimary HIV infection vs late presenters
bprimary HIV infection vs early presenters
clate presenters vs early presenters
dhealthy controls vs primary HIV infection
ehealthy controls vs late presenters
fhealthy controls vs early presenters
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presenters, and late presenters) had higher KTR compared
to healthy controls at all time points (Fig. 1a).
Immune activation
At baseline, individuals with primary HIV infection had
higher proportion of CD8 + CD38 + HLA-DR+ T cells
compared to early presenters and late presenters. Fur-
thermore, proportion of CD8 + CD38 + HLA-DR+ T
cells at baseline was lower in early presenters than in
late presenters (Table 1). Individuals with primary HIV
infection and early presenters had similar proportion of
CD4 + CD38 + HLA-DR+ T cells at baseline, both
groups lower than late presenters (Table 1). After 6 and
12 months of cART, individuals with primary HIV infec-
tion, early presenters, and late presenters had compar-
able proportions of CD8 + CD38 + HLA-DR+ and
CD4 + CD38 + HLA-DR+ T cells (Table 2). However, all
groups of HIV-infected individuals had higher proportions
of CD8 + CD38 + HLA-DR+ and CD4 + CD38 + HLA-
DR+ T cells than healthy controls at all time points
(Tables 1 and 2).
After 6 months of cART, a larger reduction (delta %)
in the proportion of CD8 + CD38 + HLA-DR+ T cells
was found in individuals with primary HIV infection
compared to early presenters and late presenters (Fig.
1b). In contrast, a larger reduction in the proportion of
CD4 + CD38 + HLA-DR+ T cells was found in late
presenters than in individuals with primary HIV infec-
tion and early presenters, both after 6 and 12 months of
follow-up (Fig. 1c).
KTR associated with reduction in immune activation, but
not with immune recovery
In individuals with primary HIV infection and early pre-
senters, baseline KTR was positively associated with pro-
portion of CD8 + CD38 + HLA-DR+ T cells at baseline
(ρ .867, p = 0.002 and ρ .544, p = 0.033, respectively),
and in early presenters also at 6 months (ρ .670,
p = 0.006, Table 3). Furthermore, baseline KTR in early
presenters was associated with CD4 + CD38 + HLA-DR
+ T cells at baseline (ρ .689, p = 0.003) and at 6 months
(ρ .711, p = 0.003) and at 12 months of follow-up (ρ .679,
p = 0.022) (Table 3). No significant associations between
baseline KTR and immune activation were found in late
presenters.
In individuals with primary HIV infection, KTR at base-
line was positively associated with the reduction in propor-
tion of CD8 + CD38 + HLA-DR+ T cells after 6 (ρ .833,
p = 0.010) and 12 months of cART (ρ.900, p = 0.037).
Furthermore, in individuals with primary HIV infection a
positive association was found between baseline KTR and
reduction in proportion of CD4 + CD38 + HLA-DR+ T
cells after 12 months of cART (ρ .900, p = 0.033) (Table 3).
In late presenters and early presenters, no associations
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Fig. 1 Kynurenine/Tryptophan ratio (KTR) in primary HIV infection, late presenters (LP) and early presenters (EP) (A). Reduction of proportion of
CD8 + CD38 + HLA-DR+ (B) and CD4 + CD38 + HLA-DR+(C) T cells at 6 and 12 months of follow-up. The numbers of samples available at each
timepoint (baseline, 6, and 12 months after initiation of cART) were: primary HIV infection (●): 14, 11, 7; late presenters (▲): 19, 10, 8; early
presenters (■): 24, 22, 8; healthy controls (+): 16. P*: comparing the four groups by using ANOVA if parametric variables or Kruksal-Wallis test if
non parametric variables. If significant (<0.05) then unpaired t-test if parametric variables or Mann-Whitney U test if non parametric variables were
used to compare two groups. Only significant differences are marked: a: primary HIV infection vs late presenters; b: primary HIV infection vs early
presenters; c: late presenters vs early presenters; d: healthy controls vs primary HIV infection; e: healthy controls vs late presenters; f: healthy
controls vs early presenters
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were found between baseline KTR and the reduction
in proportion of CD8 + CD38 + HLA-DR+ and
CD4 + CD38 + HLA-DR+ T cells after 6 and 12 months
of follow-up (Table 3).
Negative associations between baseline KTR and CD4/
CD8 ratio was found in early presenters at baseline, and
after 6 and 12 months of follow-up (data not shown).
No associations between KTR and CD4/CD8 ratio were
found in individuals with primary HIV infection or late
presenters at any time point.
No association was found between viral load and KTR at
baseline in primary HIV infection and early presenters. In
contrast, in late presenters viral load was positively associ-
ated with KTR at baseline (ρ .527, p = 0.033) (data not
shown). Furthermore, at baseline no associations were found
between viral load and proportion of CD8 + CD38 + HLA-
DR+ and CD4 + CD38 + HLA-DR+ T cells in primary HIV
infection, or early and late presenters.
Finally, no significant associations between KTR at
baseline and immune recovery were found in any of the
Table 3 Association between KTR before initiation of cART, immune activation and reduction in immune activation at baseline and
at 6, and 12 months of follow-up
Primary HIV infection N = 14 Early presenters N = 16 Late presenters N = 19
ρ pvalue ρ pvalue ρ pvalue
CD8 + CD38 + HLA-DR+
Baseline .867 .002 .534 .033 .311 .260
After 6 months of cART −.417 .265 .670 .006 .152 .676
After 12 months of cART −.800 .104 .451 .164 .145 .670
CD4 + CD38 + HLA-DR+
Baseline .267 .488 .689 .003 .530 .051
After 6 months of cART −.410 .273 .711 .003 .527 .117
After 12 months of cART −.872 .054 .679 .022 .045 .894
ΔCD8 + CD38 + HLA-DR+
After 6 months of cART .833 .010 .086 .771 .017 .966
After 12 months of cART .900 .037 .345 .328 −.041 .905
ΔCD4 + CD38 + HLA-DR+
After 6 months of cART .167 .693 .530 .051 .250 .516
After 12 months of cART .900 .033 .600 .067 .273 .446
P*: associations analyzed with Spearman’s test. Bold font if significant p value
Table 2 Proportion of CD8 + CD38 + HLA-DR+ and CD4+ CD38 + HLA-DR+ T cell subsets in HIV-infected individuals with either
primary HIV infection or chronic HIV infection before and after initiation of cART
Primary HIV infection
N = 14
Early presenters
N = 24
Late presenters
N = 19
Healthy Controls
N = 16
P
% Cells CD8 + CD38 + HLA-DR+
Baseline 44.7 (20.3)a,b,d 22.0 (13.4)b,c,f 25.6 (21.3)a,c,e 1.3 (0.8)d,e,f <.001
After 6 months of cART 6.4 (5.6)d 8.1 (5.5)f 6.5 (5.3)e NA <.001
After 12 months of cART 8.9 (8.1)d 4.0 (1.9)f 4.7 (2.8)e NA <.001
CD4 + CD38 + HLA-DR+
Baseline 5.5 (4.08)a,d 3.5 (3.0)c,f 15.5 (15.4)a,c,e 0.8 (0.6)d,e,f <.001
After 6 months of cART 1.6 (1.4)d 1.6 (1.3)f 3.3 (3.4)e NA <.001
After 12 months of cART 1.6 (0.7)d 1.1 (0.3) 2.4 (1.7)e NA <.001
Data are shown as mean (SD)
P*: comparing the four groups by using ANOVA if parametric variables or Kruksal-Wallis test if non parametric variables. If significant (<0.05) then t-test if parametric
variables or Mann-Whitney if non parametric variables were used to compare two groups. Only significant differences are marked:
aprimary HIV infection vs late presenters
bprimary HIV infection vs early presenters
clate presenters vs early presenters
dhealthy controls vs primary HIV infection
ehealthy controls vs late presenters
fhealthy controls vs early presenters
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groups HIV-infected individuals during the follow-up
period (data not shown).
Discussion
The present study extends the knowledge of the impact
of KTR in HIV infection by demonstrating that early ini-
tiation of cART is associated with lower KTR set point
after 6 and 12 months of cART when compared to initi-
ation of cART with CD4+ T cells counts less than 200
cells/μL. However, early initiation of cART did not result
in normalization of KTR. Interestingly, in early pre-
senters higher baseline KTR was found to be associated
with higher immune activation at both baseline and after
initiation of cART. Importantly, KTR was positively as-
sociated with a larger decrease in immune activation
after 6 and 12 months of cART in patients with primary
HIV infection.
Increased KTR has been described in HIV-infected in-
dividuals [6, 9, 16, 18, 30], and recent studies showed re-
duction in KTR after initiation of cART [6, 15–19]. It is
worth noticing that among the previously conducted
studies only Jenabian et al. included patients with early
HIV infection (estimated time from infection <180 days)
[15]. To our knowledge, our prospective study is the first
to compare the effect of cART on KTR in HIV-infected
patients with primary and chronic infection. At baseline,
a lower KTR was found in individuals with primary HIV
infection compared to late presenters, while primary
HIV infection had higher KTR compared to early pre-
senters. Interestingly, after 6 and 12 months of cART
primary HIV infection and early presenters had compar-
able KTR set points, while late presenters had higher
KTR set point than the two other groups. Importantly,
all groups of HIV-infected individuals consistently had
higher KTR than healthy controls during the entire
study period. Several studies have described reduction in
KTR after initiation of cART, without reaching the level
found in healthy controls [17–19]. One study even found
normalization of KTR after initiation of cART [15], but
this finding has not been confirmed. Our data support
and extend previous findings by demonstrating that early
initiation of cART either during primary HIV infection
or in early presenters has a beneficial effect on KTR set
point compared to initiation of cART in late presenters.
Immune activation and chronic inflammation have
been described as independent predictors of disease pro-
gression in HIV-infected individuals [31, 32]. Further-
more, immune activation and inflammation may be
drivers of non-AIDS comorbidity and mortality in HIV-
infected individuals [33]. Immune activation in HIV-
infected individuals is commonly assessed by co-
expression of activation markers CD38 and HLA-DR on
T-cells [34, 35]. The proportion of CD4+ and CD8+ T
cells co-expressing CD38+ and HLA-DR+ has been
described to correlate with morbidity and mortality in
HIV infected individuals [33, 36], and was therefore used
to determine immune activation in this study. The asso-
ciation between KTR and immune activation in HIV in-
fection has been described previously [15, 17, 22]. Thus,
positive associations between KTR and neopterin [17]
and between KTR and reduction in CD4/CD8 ratio [22]
in chronic HIV-infected individuals have been reported.
Furthermore, positive associations between KTR and
CD8 + CD38 + HLA-DR+ T cells in untreated early
HIV-infected patients have been described [15]. In order
to more closely examine the relationship between
immune activation and KTR in HIV-infected individuals,
we investigated associations between KTR and
CD8 + CD38 + HLA-DR+ and CD4 + CD38 + HLA-DR
+ T cells. As expected, evidence of immune activation
was found in all groups of HIV-infected individuals
with the highest proportion of immune activated cells
in individuals with primary HIV infection prior to ini-
tiation of cART. A strong positive association be-
tween KTR and proportion of CD8 + CD38 + HLA-
DR+ T cells was found at baseline in both individuals
with primary HIV infection and early presenters, in
accordance with previous studies [15]. Interestingly,
positive associations between baseline KTR and im-
mune activation after 6 and 12 months of cART were
found in early presenters.
Importantly, in individuals with primary HIV infection
higher KTR at baseline was associated with greater re-
duction in proportion of CD8 + CD38 + HLA-DR+ T
cells, both at 6 and 12 months of follow-up. Thus, a dif-
ferential effect of KTR on immune activation was found
in individuals with primary HIV infection, early pre-
senters, and late presenters. During primary HIV infec-
tion interferon-γ (IFN- γ) levels steadily increase, with a
peak approximately 3 weeks after the infection [37]. This
may be associated with a beneficial immune response,
which may help to control viral replication and to obtain
a lower viral load set-point, and thus the level of im-
mune activation during the chronic phases of the infec-
tion. IDO activity is highly enhanced by IFN- γ during
inflammation [38]. We speculated that higher KTR dur-
ing primary HIV infection is related to high IFN- γ ac-
tivity, and may be linked to an initially beneficial host
immune response, which may lead to a lower viral load
and lower chronic immune activation in the chronic
phases of infection. This beneficial association between
KTR and immune activation may be lost with the estab-
lishment of an unregulated and deleterious chronic in-
flammation and immune activation during the chronic
phases of HIV-infection, where IFN- γ levels decline to a
steady state comparable to healthy controls [39]. Further
studies in patients with primary HIV infection are war-
ranted to elucidate this mechanism.
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Little is known about the role of KTR as a predictor of
immune recovery following cART. Data are scarce and
contrasting. Thus, Byakwaga and colleagues described
KTR before cART as a predictor of immune recovery
[6], while Chen proposed opposite results [18]. Both
these studies included only patients with chronic HIV
infection. In our study, no correlation between baseline
KTR and immune recovery was found in either primary
or chronic HIV infection.
The main limitation in the present study is the num-
ber of individuals included and especially the low num-
ber of samples available at the follow-up. This may
result in type II errors. Moreover, the cohort presented
in the present study was not serocoincident. Therefore,
comparing KTR among all the groups at the time of pri-
mary HIV infection was not possible. Thus, higher KTR
in primary HIV infection compared to early presenters
may be due to the fact that individuals who initiated
cART during acute HIV sought prompt medical care be-
cause of more severe symptoms and, consequently, more
immune activation. Furthermore, the study is descrip-
tive, and conclusions on causality cannot be drawn. The
small sample size prevented us from performing other
statistical analysis, than descriptive analyses of the data.
Finally, several comparisons were made without adjust-
ing for multiple comparisons increasing the risk of type
I errors. Thus, results should be interpreted taking the a
priori hypothesis into account.
Conclusions
In conclusion, initiation of cART during either pri-
mary or early HIV infection had a beneficial effect on
KTR set point at follow-up compared to initiation of
treatment in late presenting HIV infection. However,
even in individuals with primary or early HIV infec-
tion KTR was only partly normalized. Interestingly,
baseline KTR in treatment naïve patients presenting
for care with primary or early HIV infection was
positively associated with immune activation. Further-
more, individuals who initiated cART during primary
HIV infection showed the largest reduction in im-
mune activation, and decrease in immune activation
was positively associated with baseline KTR. These
findings suggest the importance of early cART in
order to reduce KTR. Finally, an important role for
KTR in immune activation is suggested.
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